Table 4.
Univariable and multivariable predictors of recurrence.
| Variables | Univariable Analysis | Multivariable Analysis | ||
|---|---|---|---|---|
| Hazard Ratio (95% CI) | p-Value | Hazard Ratio (95% CI) | p-Value | |
| ATA risk categories | - | - | - | - |
| Low (reference) (n = 153) | - | <0.001 | - | <0.01 |
| Intermediate (n = 320) | 4.88 (1.14–20.89) | <0.05 | 5.99 (1.33–26.8) | <0.05 |
| High (n = 133) | 11.99 (2.80–51.29) | <0.01 | 14.6 (3.17–67.3) | <0.01 |
| Pre-therapy Tg ≥ 10 ng/mL (n = 198) | 4.87 (2.534–9.37) | <0.001 | 2.07 (2.25–7.78) | <0.001 |
| 12 months response to therapy (Tg + US) | - | - | - | - |
| ER (reference) (n = 219) | - | <0.01 | - | - |
| IR (n = 182) | 3.14 (1.20–8.00) | <0.05 | 3.24 (1.25–8.37) | <0.05 |
| BIR (n = 203) | 3.51 (1.40–8.78) | <0.01 | 2.88 (1.14–7.24) | <0.05 |
| SIR (n = 2) | 8.49 (2.85–25.30) | <0.001 | 17.4 (2.49–29.5) | <0.001 |
Tg (thyroglobulin), US (ultrasound), ER (excellent response), IR (indeterminate response) BIR (biochemical incomplete response), SIR (structural incomplete response).